I chair the strategic advisory board of the EU Innovative Medicines Initiative INNODIA, which conducts clinical trials aiming to halt the type 1 diabetes disease process. I am advisor to Abvance, Adocia, Altheia, Astra-Zeneca, Avotres, Bayer, Boehringer-Ingelheim, Aerami Therapeutics, Enthera, Ideal Life, Imcyse, Immunomolecular Therapeutics, Kriya, Novo Nordisk, Oramed, Orgenesis, Pila Pharma, Precigen ActoBiotics, Provention Bio, Sanofi, Precigen, Tolerion, Viacyte, and Viela Bio. I am a member of the Board of Directors of Dexcom, Intarcia, and Applied Therapeutics. I receive research funding from National Institutes of Health, Juvenile Diabetes Research Foundation, and Diabetes Research Institute Foundation. I declare no other competing interests.